1. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin.
- Author
-
Bouquié R, Deslandes G, Renaud C, Dailly E, Haloun A, and Jolliet P
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Adult, Anti-Bacterial Agents therapeutic use, Anticholesteremic Agents therapeutic use, Azithromycin therapeutic use, Cyclosporine therapeutic use, Cystic Fibrosis surgery, Drug Interactions, Gout drug therapy, Gout epidemiology, Humans, Immunosuppressive Agents therapeutic use, Kidney Failure, Chronic epidemiology, Male, Multiple Organ Failure, Pravastatin therapeutic use, Colchicine adverse effects, Gout Suppressants adverse effects, Heart-Lung Transplantation immunology, Rhabdomyolysis chemically induced
- Abstract
We report a case of colchicine-induced rhabdomyolysis in a heart/lung-transplanted man treated with cyclosporin. A treatment was to resolve an acute gouty arthritis and was started with 3 mg of colchicine the first day, then 2 mg the second and the third day, and finally 1 mg/d during 6 days. Eight days later, the patient developed multiple organ failure and rhabdomyolysis. The concentration of colchicine analyzed was greater than the standard 153 hours after his last intake. Pharmacokinetic interactions are responsible of this toxicity. Cyclosporin, pravastatin, and azithromycin are known to inhibit P-glycoprotein, which will enhance the intracellular colchicine level by acting in its bioavailability and moderating hepatic and renal excretion. Moreover, long-term treatment by cyclosporin generates chronic renal failure that will, in the same time, decrease colchicine elimination. Even short-term administration of therapeutic colchicine dose may cause colchicine-related toxicity, especially in the setting of a renal failure and/or polymedicinal treatment.
- Published
- 2011
- Full Text
- View/download PDF